chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), among ...

The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo ...

showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis 1-3 There is a need for new treatment options for atopic ...

Galderma’s Nemluvio is already approved for both atopic dermatitis and prurigo nodularis in the US. Image credit: Shutterstock / JHVEPhoto. Galderma has won approval from the European Commission (EC) ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...